Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
Dan H. Barouch*, Frank L. Tomaka, Frank Wegmann, Daniel J. Stieh, Galit Alter, Merlin L. Robb, Nelson L. Michael, Lauren Peter, Joseph P. Nkolola, Erica N. Borducchi, Abishek Chandrashekar, David Jetton, Kathryn E. Stephenson, Wenjun Li, Bette Korber, Georgia D. Tomaras, David C. Montefiori, Glenda Gray, Nicole Frahm, M. Juliana McElrathLindsey Baden, Jennifer Johnson, Julia Hutter, Edith Swann, Etienne Karita, Hannah Kibuuka, Juliet Mpendo, Nigel Garrett, Kathy Mngadi, Kundai Chinyenze, Frances Priddy, Erica Lazarus, Fatima Laher, Sorachai Nitayapan, Punnee Pitisuttithum, Stephan Bart, Thomas Campbell, Robert Feldman, Gregg Lucksinger, Caroline Borremans, Katleen Callewaert, Raphaele Roten, Jerald Sadoff, Lorenz Scheppler, Mo Weijtens, Karin Feddes-de Boer, Daniëlle van Manen, Jessica Vreugdenhil, Roland Zahn, Ludo Lavreys, Steven Nijs, Jeroen Tolboom, Jenny Hendriks, Zelda Euler, Maria G. Pau, Hanneke Schuitemaker
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
262Scopus
citations
Fingerprint
Dive into the research topics of 'Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)'. Together they form a unique fingerprint.